Literature DB >> 11092659

Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators.

M J Domanski1, C B Borkowf, L Campeau, G L Knatterud, C White, B Hoogwerf, Y Rosenberg, N L Geller.   

Abstract

OBJECTIVES: The study was done to assess patients in the Post-Coronary Artery Bypass Graft (Post-CABG) trial to determine prognostic factors for atherosclerosis progression.
BACKGROUND: Saphenous vein grafts (SVGs) are effective in relieving angina and, in certain patient subsets, in prolonging life. However, the progression of atherosclerosis in many of these grafts limits their usefulness.
METHODS: The Post-CABG trial studied moderate versus aggressive lipid-lowering and low-dose warfarin versus placebo in patients with a history of coronary artery bypass surgery and found that more aggressive lipid lowering was effective in preventing progression of atherosclerosis in SVGs, but warfarin had no effect. Using variables measured at baseline, we sought the independent prognostic factors for atherosclerosis progression in SVGs, employing the statistical method of generalized estimating equations with a logit-link function.
RESULTS: Twelve independent prognostic factors for atherosclerosis progression were found. In the order of their importance they were: maximum stenosis of the graft at baseline angiography, years post-SVG placement; the moderate low-density lipoprotein-cholesterol (LDL-C) lowering strategy; prior myocardial infarction; high triglyceride level; small minimum graft diameter; low high-density lipoprotein-cholesterol (HDL-C); high LDL-C; high mean arterial pressure; low ejection fraction; male gender; and current smoking.
CONCLUSIONS: This study identified Post-CABG patient and SVG characteristics associated with saphenous vein graft atherosclerosis progression. These data provide a basis for rational risk factor management to prevent progression of SVG atherosclerosis.

Entities:  

Mesh:

Year:  2000        PMID: 11092659     DOI: 10.1016/s0735-1097(00)00973-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

1.  Scoring system for predicting saphenous vein graft patency in coronary artery bypass grafting.

Authors:  Mahmood Reza Sarzaeem; Mohammad Hossein Mandegar; Farideh Roshanali; Ali Vedadian; Bahare Saidi; Farshid Alaeddini; Nardin Tabarestani
Journal:  Tex Heart Inst J       Date:  2010

Review 2.  Secondary revascularization after CABG surgery.

Authors:  Javier Escaned
Journal:  Nat Rev Cardiol       Date:  2012-07-10       Impact factor: 32.419

3.  Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV.

Authors:  Connie N Hess; Renato D Lopes; C Michael Gibson; Rebecca Hager; Daniel M Wojdyla; Brian R Englum; Michael J Mack; Robert M Califf; Nicholas T Kouchoukos; Eric D Peterson; John H Alexander
Journal:  Circulation       Date:  2014-09-26       Impact factor: 29.690

4.  Current State of the Art in Approaches to Saphenous Vein Graft Interventions.

Authors:  Michael Lee; Jeremy Kong
Journal:  Interv Cardiol       Date:  2017-09

5.  Saphenous vein graft near-infrared spectroscopy imaging insights from the lipid core plaque association with clinical events near-infrared spectroscopy (ORACLE-NIRS) registry.

Authors:  Barbara A Danek; Aris Karatasakis; Aya J Alame; Phuong-Khanh J Nguyen-Trong; Judit Karacsonyi; Bavana Rangan; Michele Roesle; Amy Atwell; Erica Resendes; Jose Roberto Martinez-Parachini; Rahel Iwnetu; Pratik Kalsaria; Furqan Siddiqui; James E Muller; Subhash Banerjee; Emmanouil Brilakis
Journal:  Catheter Cardiovasc Interv       Date:  2016-08-18       Impact factor: 2.692

6.  A patient with acute coronary syndrome and shock due to occlusion of both native coronaries and bypass grafts who was rescued by revascularization.

Authors:  Toru Miyoshi; Hideo Kawakami; Fumiyasu Seike; Akira Oshita; Hiroshi Matsuoka
Journal:  J Cardiol Cases       Date:  2016-08-09

7.  Preoperative graft assessment in aortocoronary bypass surgery.

Authors:  Grigore Tinica; Cristina Luca Vartic; Veronica Mocanu; Dana Baran; Doina Butcovan
Journal:  Exp Ther Med       Date:  2016-06-01       Impact factor: 2.447

8.  Depressive symptoms and the risk of atherosclerotic progression among patients with coronary artery bypass grafts.

Authors:  Gregory A Wellenius; Kenneth J Mukamal; Ambar Kulshreshtha; Sharon Asonganyi; Murray A Mittleman
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

9.  Self-reported anxiety and the risk of clinical events and atherosclerotic progression among patients with Coronary Artery Bypass Grafts (CABG).

Authors:  Joshua I Rosenbloom; Gregory A Wellenius; Kenneth J Mukamal; Murray A Mittleman
Journal:  Am Heart J       Date:  2009-09-24       Impact factor: 4.749

10.  A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.

Authors:  Olivier F Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence Title; Vladimir Dzavik; Madhu Natarajan; Juan Angel; Nuria Batalla; Natalie Alméras; Olivier Costerousse; Robert De Larochellière; Louis Roy; Jean-Pierre Després
Journal:  Can J Cardiol       Date:  2009-09       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.